Targeted drug therapy for non small cell lung cancer as researchers have learned more about the changes in non small cell lung cancer nsclc cells that help them grow they have developed drugs to specifically target these changes targeted drugs work differently from standard chemotherapy chemo drugs. Over the past decade a multitude of targeted agents have been explored in the treatment of advanced non small cell lung cancer nsclc thus far two broad classes of agents have been implemented in clinical practice a vascular endothelial growth factor vegf directed therapies and b antagonists of the epidermal growth factor receptor egfr in the former category the agent bevacizumab a monoclonal antibody has shown landmark improvements in survival when added to cytotoxic . Non small cell lung cancer nsclc accounts for approximately 80 85 of all cases of lung cancer and it is the most common cause of death in men and second only to breast cancer in women combination chemotherapy usually platinum based is currently the first line therapy of choice however the prognosis for patients with advanced nsclc remains poor with a median survival time of 8 11 months and a 1 year survival rate of 30 the treatment of nsclc is therefore a major . Targeted therapies for non small cell lung cancer biology rationale and preclinical results from a radiation oncology perspective raben d1 helfrich b bunn pa jr author information 1department of radiation oncology university of colorado health sciences center denver usa davidrabenuchscedu the epidermal growth factor receptor egfr is overexpressed in the majority of non
How it works:
1. Register Trial Account.
2. Download The Books as you like ( Personal use )